Jon Williams, CEO, Lumanity, sat down with Louis Garguilo, Outsourced Pharma, to talk about the impact of artificial intelligence (AI) on the drug development and pharmaceutical industry. AI offers potential improvements along the whole drug development and manufacturing pipeline, but this comes with the need to implement validated, auditable AI integration from the beginning: those that do will have a competitive advantage over those that cannot.

Read the full interview
via Outsourced Pharma